Zai Lab Limited ADR (ZLAB)
NASDAQ: ZLABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZLAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.63B
- EPS (TTM)
- -$1.80
- Dividend yield
- None
- 52-week range
- 15.96 – 29.02
- Day range
- 20.02 – 21.15
- Volume / Avg
- 1.44M / 991.34K
- Beta
- —
- Shares outstanding
- 124.84M
52-week range
ZLAB stock today
Zai Lab (ZLAB) closed at $21.03 on Nov 20, down 4.06% (-$0.89), versus the S&P 500's 3.70% decline. Shares are 27.5% below their 52-week high of $29.02, set on Nov 9, 2026 and 31.8% above the 52-week low of $15.96, in the middle of the past year's range. ZLAB is up 19.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 5.0%.
Zai Lab has posted a net loss over the last twelve months (EPS of -$1.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Zai Lab
Company profileZai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ying Du Ph.D.
- Headquarters
- Pudong
- Employees
- 1,784
- IPO year
- 2017
- Website
- zailaboratory.com
Financial highlights
Full financialsIn fiscal 2025, Zai Lab generated $460.2 million in revenue, up 15.3% from fiscal 2024, its 7th consecutive year of revenue growth. Zai Lab reported a net loss of $175.5 million, compared with a loss of $257.1 million a year earlier. Gross margin was 58.6% (down from 63.1%) and operating margin -49.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $460.16M | $398.99M | $266.72M | $215.04M | $144.31M |
| Growth | +15.33% | +49.59% | +24.03% | +49.01% | +194.77% |
| Net income | $-175.54M | $-257.10M | $-334.62M | $-443.29M | $-704.47M |
| EPS (diluted) | $-0.16 | $-0.26 | $-0.35 | $-0.46 | $-0.76 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$34.21+62.67%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.04 vs —
ZLAB news
All ZLAB newsZai Lab peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XNCRXencor Inc. | 33.26 | -2.21% | $2.50B | vs ZLAB |
| IDYAIDEAYA Biosciences Inc. | 25.56 | -2.33% | $2.47B | vs ZLAB |
| SLSSELLAS Life Sciences Group Inc. | 13.66 | -8.08% | $2.78B | vs ZLAB |
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs ZLAB |
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs ZLAB |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs ZLAB |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs ZLAB |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs ZLAB |
Indexes, lists and sector
Zai Lab stock FAQ
What is Zai Lab's stock price today?
ZLAB last traded at $21.03 as of Nov 20, 4:00 PM EST, down 4.06% on the day. Prices are delayed at least 15 minutes.
Who is Zai Lab's CEO?
Dr. Ying Du Ph.D. is the chief executive officer of Zai Lab Limited ADR, which has about 1,784 employees.
What is the ZLAB 52-week high?
The 52-week high for ZLAB is $29.02 and the 52-week low is $15.96. The stock is currently 27.5% below its high.